Miv Therapeutics, Inc. (IVT) Tops Q4 EPS by 5c; offers guidance

Miv Therapeutics, Inc. (NYSE: IVT) reported Q4 EPS of $0.03, $0.05 better than the analyst estimate of ($0.02).

GUIDANCE:

Miv Therapeutics, Inc. sees FY2026 EPS of $0.16-$0.22, versus the consensus of $0.25.

For earnings history and earnings-related data on Miv Therapeutics, Inc. (IVT) click here.

You May Also Be Interested In

• Nomura/Instinet Upgrades Genting Singapore (GENS:SP) (GIGNY) to Neutral
• Desjardins Downgrades Alithya Group Inc. (ALYA:CN) (ALYA) to Hold
• UBS Upgrades Pagegroup Plc. (PAGE:LN) (MPGPY) to Buy